Animal tumor models for PET in drug development

被引:0
|
作者
Jun Toyohara
Kiichi Ishiwata
机构
[1] Tokyo Metropolitan Institute of Gerontology,Positron Medical Center
来源
关键词
Animal tumor models; Positron emission tomography; Drug development; Anticancer agent;
D O I
暂无
中图分类号
学科分类号
摘要
Positron emission tomography (PET) is being increasingly applied to animal tumor models due to the need for proof-of-concept testing and preclinical efficacy studies of anticancer agents. Regardless of the nature of an experiment, investigators should carefully select a suitable animal tumor model as part of the experimental design. This review introduces sources of information and the guiding principles regarding applicability of various animal tumor models for PET in anticancer agent development especially for small animals.
引用
收藏
页码:717 / 731
页数:14
相关论文
共 50 条
  • [1] Animal tumor models for PET in drug development
    Toyohara, Jun
    Ishiwata, Kiichi
    ANNALS OF NUCLEAR MEDICINE, 2011, 25 (10) : 717 - 731
  • [2] Role of human and animal PET studies in drug development
    Lammertsma, AA
    QUANTITATION IN BIOMEDICAL IMAGING WITH PET AND MRI, 2004, (1265): : 3 - 11
  • [3] TUMOR-MODELS IN DRUG DEVELOPMENT
    GRISWOLD, DP
    HARRISON, SD
    CANCER AND METASTASIS REVIEWS, 1991, 10 (03) : 255 - 261
  • [4] Systematic development and characterization of orthotopic animal tumor models: A proactive approach to mimic patients' tumor microenvironments for drug discovery
    Yang, WenQing
    Yuan, Xusheng
    Yang, Guangliang
    Tong, Xiaojun
    Ding, Weiqun
    Zhang, Qiuxia
    Lu, Feng
    Yang, Zhijian
    CANCER RESEARCH, 2024, 84 (07)
  • [5] Animal models of α-synucleinopathy for Parkinson disease drug development
    James B. Koprich
    Lorraine V. Kalia
    Jonathan M. Brotchie
    Nature Reviews Neuroscience, 2017, 18 : 515 - 529
  • [6] ANIMAL-MODELS IN DRUG DEVELOPMENT - HISTORICAL ASPECTS
    GAUNT, R
    ONCOLOGY, 1977, 34 (03) : 94 - 95
  • [7] The value of animal models for drug development in multiple sclerosis
    Friese, Manuel A.
    Montalban, Xavier
    Willcox, Nick
    Bell, John I.
    Martin, Roland
    Fugger, Lars
    BRAIN, 2006, 129 : 1940 - 1952
  • [8] Animal models of hyperfunctioning parathyroid diseases for drug development
    Imanishi, Yasuo
    Inaba, Masaaki
    Kawata, Takehisa
    Nishizawa, Yoshiki
    EXPERT OPINION ON DRUG DISCOVERY, 2009, 4 (07) : 727 - 740
  • [9] Stroke drug development - Usually, but not always, animal models
    Donnan, GA
    Davis, SM
    STROKE, 2005, 36 (10) : 2326 - 2326
  • [10] Animal models of α-synucleinopathy for Parkinson disease drug development
    Koprich, James B.
    Kalia, Lorraine V.
    Brotchie, Jonathan M.
    NATURE REVIEWS NEUROSCIENCE, 2017, 18 (09) : 515 - 529